Sagimet Biosciences (SGMT) Change in Accured Expenses (2022 - 2026)

Sagimet Biosciences' Change in Accured Expenses history runs 5 years deep, the most recent figure standing at $637000.0 for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 81.21% year-over-year to $637000.0 in Q1 2026; TTM through Mar 2026 was -$1.8 million, a 155.87% decrease from a year earlier, with the FY2025 full-year figure at $929000.0, up 202.43% from the prior year.
• Change in Accured Expenses rose to $637000.0 in Q1 2026 per SGMT's latest filing, from -$4.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $3.4 million in Q1 2025 and bottomed at -$4.0 million in Q4 2025.
• The 5-year median for Change in Accured Expenses is $320000.0 (2023), against an average of $55266.7.
• Biggest YoY gain for Change in Accured Expenses was 533.5% in 2025; the steepest drop was 994.82% in 2025.
• Year by year, Change in Accured Expenses stood at -$1.0 million in 2022, then jumped by 131.84% to $320000.0 in 2023, then jumped by 38.75% to $444000.0 in 2024, then sank by 994.82% to -$4.0 million in 2025, then soared by 116.03% to $637000.0 in 2026.
• Per Business Quant, the three latest SGMT Change in Accured Expenses figures stand at $637000.0 (Q1 2026), -$4.0 million (Q4 2025), and $1.6 million (Q3 2025).